FMR LLC boosted its position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,448,170 shares of the biopharmaceutical company’s stock after purchasing an additional 13,468 shares during the period. FMR LLC owned approximately 15.00% of Intercept Pharmaceuticals worth $448,331,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Intercontinental Wealth Advisors LLC bought a new stake in Intercept Pharmaceuticals during the fourth quarter valued at about $34,000. Advisor Group Inc. boosted its holdings in Intercept Pharmaceuticals by 63.5% during the fourth quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 287 shares during the period. Strs Ohio boosted its holdings in Intercept Pharmaceuticals by 30.0% during the fourth quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Intercept Pharmaceuticals by 14.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 183 shares during the period. Finally, Stifel Financial Corp bought a new stake in Intercept Pharmaceuticals during the fourth quarter valued at about $228,000. Hedge funds and other institutional investors own 70.24% of the company’s stock.
In related news, Director Srinivas Akkaraju sold 23,438 shares of the firm’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $128.78, for a total transaction of $3,018,345.64. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Shapiro sold 2,000 shares of the firm’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $111.51, for a total transaction of $223,020.00. Following the sale, the insider now owns 42,543 shares in the company, valued at $4,743,969.93. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,504 shares of company stock worth $3,969,947. Insiders own 4.90% of the company’s stock.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($2.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.42) by ($0.55). Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. The business had revenue of $53.30 million during the quarter, compared to the consensus estimate of $52.53 million. During the same period in the previous year, the business posted ($4.43) earnings per share. Intercept Pharmaceuticals’s revenue was up 41.4% compared to the same quarter last year. On average, sell-side analysts expect that Intercept Pharmaceuticals Inc will post -9.13 EPS for the current year.
A number of equities research analysts have issued reports on ICPT shares. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a report on Monday, December 31st. Raymond James reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, February 14th. Laidlaw upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $99.00 to $130.00 in a research note on Monday, January 14th. Jefferies Financial Group increased their price target on shares of Intercept Pharmaceuticals to $150.00 and gave the stock a “buy” rating in a research report on Monday, January 28th. Finally, Needham & Company LLC raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Thursday, January 24th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the stock. Intercept Pharmaceuticals currently has an average rating of “Buy” and an average price target of $144.05.
WARNING: “Intercept Pharmaceuticals Inc (ICPT) Shares Bought by Fmr LLC” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/fmr-llc-has-448-33-million-holdings-in-intercept-pharmaceuticals-inc-icpt.html.
Intercept Pharmaceuticals Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Article: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.